European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 489-495 , October 2007

Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: An Egyptian study

  • Sahar S. Bessa

      Affiliations

    • Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt
    • Corresponding Author InformationCorresponding author.
    • ,
  • Soha M. Hamdy

      Affiliations

    • Chemistry Department, Division of Biochemistry, Faculty of Science, Fayoum University, Egypt
    • ,
  • Ehab M.M. Ali

      Affiliations

    • Chemistry Department, Division of Biochemistry, Faculty of Science, Tanta University, Tanta, Egypt

Received 22 July 2006 ,Revised 23 January 2007 ,Accepted 9 February 2007.

References 

  1. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med. 1993;329:977–986
  2. Marre M, Hadjadj S, Bouhanick B. Hereditary factors in the development of diabetic renal disease. Diabetes Metab. 2000;26(Suppl 4):30–36
  3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–412
  4. Bowman BH. Haptoglobin. In:  Bowman BH editors. Hepatic plasma proteins. San Diego: Academic Press; 1993;p. 159–167
  5. Lim SK, Kim H, Lim SK, bin Ali A, Lim YK, Wang Y, et al. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood. 1998;92:1870–1877
  6. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–1600
  7. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure–function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98:3693–3698
  8. Okazaki T, Nagai T. Difference in hemoglobin-binding ability of polymers among haptoglobin phenotypes. Clin Chem. 1997;43:2012–2013
  9. Sadrzadeh SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol. 2004;121:S97–S104[Suppl]
  10. Delanghe J, Cambier B, Langlois M, Byzere M, Neels H, De Bacquer D, et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis. 1997;132:215–219
  11. Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis. 1999;145:287–292
  12. Densem CG, Wassel J, Brooks NH, Yonan N, Keevil B. Haptoglobin polymorphism influences the development of cardiac transplant vasculopathy. J Heart Lung Transplant. 2001;20:151
  13. de Bacquer D, de Backer G, Langlois M, Delanghe J, Kesteloot H, Komitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis. 2001;157:161–166
  14. Roguin A, Hochberg I, Nikolsky E, Markiewicz W, Meisel SR, Hir J, et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 2001;87:330–332
  15. Roguin A, Ribichini F, Ferrero V, Matullo G, Herer P, Wijns W, et al. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol. 2002;89:806–810
  16. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002;40:1984–1990
  17. Mustafa S, Vukovich T, Prikoszovich T, Winzer C, Schneider B, Esterbauer H, et al. Haptoglobin phenotype and gestational diabetes. Diabetes Care. 2004;27:2103–2107
  18. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16:78–82
  19. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia. 2003;46:1402–1407
  20. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78
  21. Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes. 1995;44:1233–1238
  22. Guigliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257–267
  23. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications. Curr Opin Endocrinol. 1997;3:277–284
  24. Spooren PF, Lekker JF, Vermes I. Micral test a qualitative dipstick test for microalbuminuria. Diabetes Res Clin Pract. 1992;18:83–87
  25. Teppo AM. Immunoturbidimetry of albumin and immunoglobulin G in urine. Clin Chem. 1982;28:1359–1361
  26. Maquart F, Giller P, Bernard J. Method for specially measuring of hemoglobin A1c with disposable commercial ion exchange column. Clin Chim Acta. 1980;108:329
  27. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136–2141
  28. Ida N, Sakurai S, Hosaka T, Kunitomo T, Shimazu T, Masuura Y, et al. Establishment of strongly neutralizing antibody to human IL-6 and its epitope analysis. Biochem Biophys Res Commun. 1989;165:728–734
  29. Elson EC. Quantitative determination of serum haptoglobin. Am J Clin Pathol. 1974;62:655
  30. Wassell J, Keevil B. A new method for haptoglobin phenotyping. Ann Clin Biochem. 1999;36:609–612
  31. Hochberg I, Roguin A, Nikolsky E, Chanderashekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis. 2002;161:441–446
  32. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435–441
  33. Nakhoul FM, Zoabi R, Kanter Y, Zoabi M, Skorecki K, Hochberg I, et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia. 2001;44:602–604
  34. Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000;343:969–970
  35. Nakhoul FM, Marsh S, Hochberg I, Leibu R, Miller BP, Levy AP. Haptoglobin genotype as a risk factor for diabetic retinopathy. J Am Med Assoc. 2000;284:1244–1245
  36. Awadallah S, Hamad M. A study of haptoglobin phenotypes in patients with chronic renal failure. Ann Clin Biochem. 2003;40:680–683
  37. Burbea Z, Nakhoul F, Rosenberg S, Zoabi R, Skorecki K, Hochberg I, et al. Role of haptoglobin phenotype in end-stage kidney disease. Nephron Exp Nephrol. 2004;97:e71–e76
  38. Burbea Z, Nakhoul F, Zoabi R, Hochberg I, Levy NS, Benchetrit S, et al. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem. 2004;41:469–473
  39. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the hemoglobin scavenger receptor. Nature. 2001;409:198–201
  40. Schaer DJ. The macrophage hemoglobin scavenger receptor (CD163) as a genetically determined disease- modifying pathway in atherosclerosis. Atherosclerosis. 2002;163:199–201
  41. McMillan DE. Increased levels of acute phase serum proteins in diabetes. Metabolism. 1989;38:1042–1046
  42. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42:53–61
  43. Gomes MB, Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract. 2004;66:31–39
  44. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–1710
  45. Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron. 2000;85:81–85
  46. Abdel Aleim A, Mohie M, Abdel Rahman EM, Gomaa S. Urinary and serum IL-6 assay in patients with non insulin dependent diabetes and its roles in pathogenesis of nephropathy. Egypt J Intern Med. 2004;16:51–60
  47. Yasuhiko T, Sonki K, Hikaru K, Isao S. Detection of serum IL-6 in patients with diabetic nephropathy. Nephron. 1994;68:284–285
  48. Munzel T, Keaney JF. Are ACE inhibitors a magic bullet against oxidative stress?. Circulation. 2001;104:1571–1574
  49. Guijarro C, Egido J. Transcription factor-kB (NF-kB) and renal disease. Kidney Int. 2001;59:415–424

PII: S0953-6205(07)00161-6

doi: 10.1016/j.ejim.2007.02.033

European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 489-495 , October 2007

Article Tools

* Image Usage & Resolution